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CNS central nervous system 
CSF cerebrospinal fluid 
DMSO dimethylsulfoxide C2H6OS 
EAE experimental autoimmune encephalomyelitis 
FACS fluorescence-activated cell sorting 
FS forward scatter 
IFN interferon 
IgM, G, A, E immunoglobulin M, G, A, E 
IL interleukin 
HLA human leukocyte antigen 
LSM lymphocyte separation medium 
MAL maackia amurensis lectin, common name: maackia 
MBP myelin basic protein  
MOP myelin oligodendrocyte protein 
MS multiple sclerosis 
nTregs naturally occurring regulatory T cells 
PBMC peripheral blood  mononuclear cells 
PBS phosphate buffered saline 
PLP proteolipid protein  
PMA phorbol 12-myristate 13-acetate  
RRMS relapsing-remitting multiple sclerosis 
SEM standard error of the mean 
SNA sambucus nigra lectin, common name: elderberry lectin 
SS sideward scatter 
STAT signal transducer and activator of transcription 
Th cells T helper cells 
Tregs regulatory T cells 
UEA ulex europaeus agglutinin, common name: gorse, furze 
VCAM vascular adhesion molecule 
VLA very late activation antigen  
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1. Introduction  
The immune system is made up of various cell types and proteins that help to 
clear the body of potential pathogens and keep infections in check. 
Immunodeficiency and autoimmunity are unfavourable immune disorders that 
result from the immune response being either too weak or too strong. This 
study describes phenotypical characteristics of cells of the immune system that 
are associated with multiple sclerosis and in particular those involved in 
immunomodulatory treatment. Specifically, changes in the glycan structure on 
the surface of cells that are associated with MS immunomodulatory treatment 
(interferon-β and natalizumab) are assessed. This chapter provides an 
overview of the components of the immune system that are examined in the 
study.  
Multiple sclerosis 
Multiple sclerosis is a chronic inflammatory disease of the central nervous 
system that mainly occurs in young adults. It is characterised by the loss of the 
myelin sheath around axons, which compromises the conductibility of the 
affected nerves. The demyelination of axons leaves so-called MS plaques that 
can often be found in the periventricular white matter, the optic nerves, and the 
white matter of the spinal cord (Kumar, Cotran et al. 2003). MS plaques often 
appear as astrocytic scars with relatively well preserved axons (Noseworthy, 
Lucchinetti et al. 2000). The most common form of MS is relapsing-remitting 
MS (RRMS) where patients suffer recurring exacerbations of neurologic 
dysfunction but also experience phases of recovery. Other forms include 
secondary progressive MS, which is marked by a continuous deterioration of 
clinical symptoms and evolves from RRMS, and primary progressive MS, 
which directly begins with a progressive decline in neurologic function 
(Compston and Coles 2008). Depending on the site of the lesions, patients 
suffering from MS may present with neurological symptoms such as unilateral 
optic neuritis, diplopia, Lhermitte’s sign (the sensation of a general electric 
shock caused by flexion of the neck), limb weakness, clumsiness, gait ataxia, 
and neurogenic bladder and bowel symptoms (Compston and Coles 2008).  
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The etiopathogenesis of MS has not yet been completely understood. Most 
immunologists believe that MS is an autoimmune disorder. An increased 
concordance rate in twins suggests that genetic factors influence the risk of 
developing MS (Mumford, Wood et al. 1994). Moreover, an association with 
HLA class II polymorphisms Dw2 and DR2 has long been known (as reviewed 
by Dyment, Ebers et al. 2004). No single gene was found to be associated with 
MS and it is instead viewed as a polygenic disorder (Fernald, Yeh et al. 2005). 
It has been observed that the risk of developing MS was associated with the 
MS prevalence in the country where people lived at a young age (Elian, 
Nightingale et al. 1990). Thus, environmental factors, such as an infection with 
Epstein-Barr virus, are also discussed (Serafini, Rosicarelli et al. 2007).  
The primary target of CNS-inflammation in MS is unclear. However, possible 
candidates for immunogenic brain-antigens are oligopeptides derived from 
myelin basic protein (MBP), proteolipid protein (PLP), or myelin 
oligodendrocyte protein (MOP) (Murphy, Travers et al. 2012, p. 636). It is 
believed that in order to be recognised by T cells these brain-antigens are 
presented by antigen-presenting cells to naive T cells in places like deep 
cervical lymph nodes (Hatterer, Davoust et al. 2006). The encounter with the 
antigen turns T helper cells into activated T memory cells. In addition, an 
inflammation of the brain set up by a trigger that can still not be pinpointed, 
increases the permeability of the blood vessels (as reviewed by Frohman, 
Racke et al. 2006). Consequently, activated T memory cells enter the site of 
inflammation and are promptly re-activated by local and infiltrating antigen-
presenting cells (as reviewed by Fletcher, Lalor et al. 2010; Lucchinetti, 
Popescu et al. 2011). As a result, the newly activated T cells proliferate and 
secrete cytokines, which in turn exacerbates the perivascular inflammation and 
attracts Th1 cells, Th17 cells and myeloid cells via pial vessels (Lucchinetti, 
Popescu et al. 2011). Subsequently, innate immune cells and plasma cells 
producing autoreactive antibodies aggravate the inflammation which impinges 
on oligodendrocytes and eventually results in demyelination of neurites 
(Lucchinetti, Popescu et al. 2011).  
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T helper 1 cells 
Phenotype, function and differentiation of human Th1 cells 
T helper 1 (Th1) cells can be distinguished from other T helper cells by their 
production of specific cytokines such as interferon-γ (IFN-γ) and interleukin-2 
(IL-2) (Mosmann and Coffman 1989).  
Under physiological conditions Th1 cells are involved in the defence against 
intracellular pathogens. They help to keep bacterial infections in check by 
activating infected macrophages and thus increasing their intracellular 
microbicidal power (Murphy, Travers et al. 2012, p. 360). In many infections, 
either Th1 or Th2 cells get the upper hand and become predominant during the 
course of the inflammatory reaction. Whether Th1 or Th2 cells play a more 
important role in a given infection is usually dictated by the kind of infection and 
the cytokines present in the local environment during the early stages of T cell 
activation (Murphy, Travers et al. 2012, p. 362).  
The differentiation of naive CD4 T into Th1 cells requires the exposure to IFN-γ 
and IL-12 during the initial priming period (Zhu, Yamane et al. 2010). Mature 
Th1 cells that recognise antigen on target cells increase their IFN-γ production 
which in turn has a knock-on effect on further Th1 cell differentiation (Murphy, 
Travers et al. 2012, p. 362).  
Research groups have differentiated purified human CD4+ T helper cells into 
Th1 cells by activating them in the presence of IL-12 and anti-IL-4. Roozendaal 
and colleagues report that the neutralisation of IL-4 with blocking antibodies 
leads to the desired differentiation into Th1 cells, even without the addition of 
IFN-γ (Roozendaal, Vellenga et al. 2001; Heijink, Vellenga et al. 2003). 
Another research group has differentiated purified human CD4+ T helper cells 
into Th1 cells by activating them with anti-CD3 and anti-CD28 in the presence 
of only IL-12. IL-2 was added as a T cell growth factor (Simhadri, Mariano et al. 
2011).  
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Involvement of human Th1 cells in MS 
Inflammation of the brain increases the permeability of blood vessels around 
the brain and allows Th1 cells to extravasate and exacerbate the inflammation 
by secreting IFN-γ. As a result, IFN-γ attracts and activates myeloid cells which 
in turn induce more T cells, B cells, and innate immune cells to travel to the site 
of inflammation (Murphy, Travers et al. 2012, p. 637).  
Both Th17 and Th1 cells play a role in the pathogenesis of multiple sclerosis. 
The phenotype of Th17 is considered unstable and Th17 cells can turn into 
Th1 cells (Abromson-Leeman, Bronson et al. 2009). Thus, further research 
might be necessary to determine whether Th17 or Th1 cells play the more 
dominant role in MS (Fletcher, Lalor et al. 2010). Mouse studies have shown 
that either of the two cell types, Th1 or Th17, has the capacity to cause EAE 
and that, as a consequence, either signature cytokine (IFN-γ or IL-17) can 
precipitate this kind of inflammation (as reviewed by Fletcher, Lalor et al. 
2010).  
Th2 cells 
Phenotype, function and differentiation of human Th2 cells 
Th2 cells are characterised by their secretion of a typical set of cytokines, such 
as IL-4, IL-5 and IL-10 and IL-13 (Mosmann and Coffman 1989).  
By secreting IL-4 and binding to the CD40 molecule on B cells Th2 cells help to 
initiate the clonal expansion of B cells (Murphy, Travers et al. 2012, pp 391-
392).  
The most potent cytokine that favours the differentiation of naive T cells into 
Th2 cells is IL-4. It is secreted from eosinophils, basophils, mast cells, natural 
killer T cells, and Th2 cells (Mowen and Glimcher 2004). Th2 cells can be 
obtained in vitro by polarising purified naive human CD4 T cells with IL-4 plus 
anti-IL-12 (Roozendaal, Vellenga et al. 2001; Heijink, Vellenga et al. 2003).  
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Involvement of human Th2 cells in MS 
In the past, Th2 cells were considered to have immunoregulatory effects. Thus, 
efforts were made to switch the T cell response from Th1 to Th2. However, 
these attempts proved unsuccessful and immunomodulatory effects were 
subsequently associated with regulatory T cells (Tregs) instead (Murphy, 
Travers et al. 2012, p 619). In fact, Th2 cells have been ascribed to a number 
of auto-reactive immune responses such as Omenn's syndrome, reduced 
protection against some intracellular pathogens, chronic graft versus host 
disease (GVHD), atopic disorders, and some systemic autoimmune diseases 
(as reviewed by Romagnani 1996).  
Th17 cells 
Phenotype, functions and differentiation of human Th17 cells  
Th17 cells are a subset of CD4+ T helper cells that differ from Th1 and Th2 
cells in that they express the IL-23-receptor, transcription factor RORγt and the 
CC chemokine R6. Furthermore, Th17 cells secrete their namesake cytokine 
IL-17. They effectively induce the production of IgM, IgG, and IgA, but not IgE 
in B cells (as reviewed by Romagnani 2008). Th17 cells bring about 
inflammation by secreting IL-17, which triggers a cascade of inflammatory 
mediators and eventually culminates in the invasion of innate effector cells, 
such as neutrophils and macrophages (Mills 2008; Murphy, Travers et al. 
2012, p. 434).  
The fact that Th17 cells are less susceptible to the immuno-suppressive effects 
of FoxP3+ regulatory T cells than Th1 and Th2 cells (Annunziato, Cosmi et al. 
2007) highlights the detrimental role they play in autoimmunity.  
Interestingly, one T helper subset in humans can produce IL-17 as well as IFN-
γ (Annunziato, Cosmi et al. 2007; Romagnani 2008; Shi, Cox et al. 2008; 
Abromson-Leeman, Bronson et al. 2009).  
Despite some differing opinions among experts there is the general agreement 
that IL-23 and IL-1β drive the differentiation of human naive T helper cells 
towards Th17 cells (Wilson, Boniface et al. 2007). Some authors report that 
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either IL-1β or IL-23 is able to induce Th17 differentiation alone (Wilson, 
Boniface et al. 2007). Another study focuses on T memory cells and concludes 
that bacteria can prompt dendritic cells to produce IL-23 and IL-1 both of which 
are vital in driving memory T cells towards Th17 development (van Beelen, 
Zelinkova et al. 2007). While IL-1β and IL-6 can polarise T memory cells to turn 
into Th17, the differentiation of human naive T cells into Th17 cells requires 
TGF-β and IL-21 (Yang, Anderson et al. 2008). In sum, IL-1, IL-6, IL-21, IL-23 
and TGF-β have all been shown to be involved in human Th17 differentiation in 
vitro (Wilson, Boniface et al. 2007; Yang, Anderson et al. 2008).  
Differentiating human Th17 cells has proven difficult as discrepant 
combinations of cytokines have been suggested by several groups (as 
reviewed by Valmori, Raffin et al. 2010). Valmori, Raffin and colleagues report 
that Th17 originate from FoxP3+ Treg cells and that they can be obtained by 
differentiating naive Tregs into Th17 in the presence of IL-2 and IL-1β and that 
adding IL-23 and TGF-β yields an increased number of Th17 cells (Valmori, 
Raffin et al. 2010).  
Involvement of Th17 cells in MS 
Th17 cells and their pro-inflammatory effects have been linked to numerous 
autoimmune disorders. Tissues from systemic lupus erythematosus, 
rheumatoid arthritis, and psoriasis showed signs of Th17-infiltration (Sallusto 
and Lanzavecchia 2009). Their pathogenic role in MS and EAE is now widely 
recognised (Fletcher, Lalor et al. 2010). The number of Th17 cells in the 
peripheral circulation increases with exacerbation and decreases under 
interferon therapy (Durelli, Conti et al. 2009). In addition, IL-17 producing cells 
could be detected in active areas of MS brain lesions besides CD8+ cells and 
glial cells (Lock, Hermans et al. 2002; Tzartos, Friese et al. 2008; Montes, 
Zhang et al. 2009). Furthermore, Th17 cells have been shown to travel across 
the blood brain barrier faster than Th1 cells and impinge on neurons through 
the secretion of cytolytic granzyme B (Kebir, Kreymborg et al. 2007). It has 
been postulated that Th17 cells permeabilise the blood brain barrier through IL-
17 and IL-22 and thus pave the way for the invasion of other pro-inflammatory 
CD4+ cells and soluble molecules (Kebir, Kreymborg et al. 2007).  
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Regulatory T cells 
Phenotype and differentiation of regulatory T cells 
Regulatory T cells (Tregs) are a heterogeneous group of CD4+CD25+ cells. 
One of their key features is the ability to detect autoreactive lymphocytes and 
to suppress them through various mechanisms.  
There are two types of regulatory T cells:  
One of the types of regulatory T cells are naturally occurring Tregs (nTregs). 
Recent research suggests that nTregs can be classified into activated 
suppressor Tregs (FoxP3hiCD45RA-), resting suppressor Tregs 
(Foxp3loCD45RA+), and non-suppressor Tregs (Foxp3loCD45RA-) according 
to their function and phenotype (Miyara, Yoshioka et al. 2009).  
Natural Tregs develop from moderately auto-reactive naive T lymphocytes 
after they escape the selection process in the thymus. On encountering self-
antigen presented by dendritic cells, however, they do not differentiate into 
auto-reactive cells that could elicit an immune response. On the contrary, they 
prevent other self-reactive cells from differentiating into T effector cells or 
interfere with the function of self-reactive T effector cells. (Murphy, Travers et 
al. 2012, pp. 364-365) 
The other type of Tregs is called adaptive or induced Tregs (iTregs). This type 
of Tregs evolves in a contact-dependant way from auto-reactive CD4+ cells 
that recognise self antigen presented by immature dendritic cells.  
Secretion of TGF-β by immature dendritic cells in the absence of pro-
inflammatory cytokines induces the development of iTregs (Valencia and 
Lipsky 2007). 
Functions of regulatory T cells 
There are various mechanisms through which Tregs can control adaptive 
immune responses:  
CTLA-4 on the surface of Tregs competes with naive T cells for the B7 
molecule on antigen presenting cells. B7 functions as an important co-
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stimulatory signal for naive T cells which is why blocking of B7 by Tregs 
interrupts T cell activation. Furthermore, Tregs secrete the cytokines IL-10 and 
TGF-β both of which inhibit T cell proliferation (Murphy, Travers et al. 2012, p. 
364-365).  
Involvement of human regulatory T cells in MS and interaction 
with T effector cells 
Although there is no difference between the frequency of Tregs in the 
peripheral blood of healthy individuals and MS-patients, it is the suppressive 
function of Tregs that is decreased in MS (Viglietta, Baecher-Allan et al. 2004; 
Feger, Luther et al. 2007; Valencia and Lipsky 2007). Fletcher, Lonergan and 
colleagues (2009) found that a CD39+ subset of Tregs fails to suppress IL-17 
secretion in patients with multiple sclerosis, while the secretion of both IFN-γ 
and IL-17 was decreased in healthy donors.  
B cells 
While many studies and experiments focus on the role of T cells in the 
pathology and prevention of MS, the role of B cells has perhaps been 
underrated.  
Since oligoclonal bands (patterns of immunoglobulin G of which some can only 
be detected in the CSF but not in the serum of a patient) are a common 
occurrence in MS patients, the involvement of B cells and plasma cells in the 
pathogenesis of MS has long been suspected (Frohman, Racke et al. 2006). 
Even though more recent studies confirm that some of these intrathekal 
antibodies are specific for brain antigen the exact role of B cells in MS seems 
to be more complex and remains unclear (Ray, Mann et al. 2011). However, 
since positive effects of B cell blockage with rituximab (an antibody directed at 
the CD20 molecule on B cells) have been reported more research could be 
conducted into the role of B cells in autoimmunity (Naismith, Piccio et al. 2010).  
Treatment of relapsing-remitting multiple sclerosis 
MS medication can be divided into two categories: Symptom management 
medication and disease modifying drugs.  
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An example for symptom management medication is corticosteroids such as 
methylprednisolone and dexamethasone. Corticosteroids can relieve 
symptoms and speed up recovery from an acute relapse (Miller, Weinstock-
Guttman et al. 2000).  
Treatment with disease modifying drugs involves immunemodulators such as 
interferon-β, natalizumab, glatiramer acetate and Fingolimod. The aim of 
disease modifying treatment is to delay the accumulation of physical disability 
and to reduce the frequency of relapses (Compston and Coles 2008).  
In this study changes on the surface of cells from RRMS-patients receiving 
interferon-β or natalizumab are assessed. The following two articles will thus 
treat those two immunemodulators in greater detail:  
Interferon-β 
Interferon-β (IFN-β) is a type I interferon (Liu 2005). Type I interferons are 
pleiotropic cytokines that not only play a role in fighting off viral infections but 
also act as messengers that mediate a host of cellular functions (van Boxel-
Dezaire, Zula et al. 2010).  
Together with glatiramer acetate, IFN-β is currently licensed as a first-line 
treatment in RRMS (de Seze, Borgel et al. 2012). The clinical effects of IFN-β 
treatment are: reduced MRI lesion activity, reduced brain atrophy, increased 
time to reach clinically definite MS after the onset of neurological symptoms, 
decreased relapse rate and reduced risk of sustained disability progression (as 
reviewed by Kieseier 2011).  
The mechanism of action of IFN-β is multifactorial and only partly understood. 
IFN-β reduces the secretion of the inflammatory cytokine IFN-γ by CD4+ cells 
in RRMS (Skrzipek, Vogelgesang et al. 2011). Since IFN-γ is a signature 
cytokine of Th1 cells this is in line with the finding that IFN-β also skews T cell 
differentiation towards the Th2 phenotype (Martin-Saavedra, Gonzalez-Garcia 
et al. 2008). More recent research shows that, depending on the dosage, IFN-
β either increases IL-4 secretion or has no effect on it (Skrzipek, Vogelgesang 
et al. 2011). This suggests that IFN-β does not compromise Th2 activity. 
Another anti-inflammatory mechanism of IFN-β is instrumented by an 
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increased expression of Bcl-XL in nTregs which prevents them from 
undergoing apoptosis (Martin-Saavedra, Gonzalez-Garcia et al. 2008). 
Furthermore, IFN-β causes the differential induction of STAT and thus 
increases the survival of primary human B cells and CD4+ cells. At the same 
time, IFN-β leads to the apoptosis of monocytes (van Boxel-Dezaire, Zula et al. 
2010). Previous observations have suggested the involvement of IFN-β with 
the adhesion cascade which could hinder activated T helper cells from leaving 
the blood vessels and setting up an inflammation in the CNS (Calabresi, 
Tranquill et al. 1997).  
Natalizumab 
Natalizumab is a humanised monoclonal antibody directed against the α4 
subunit of the α4β1 integrin (also called very late activation antigen 4, VLA-4) 
and α4β7 integrin. Natalizumab is a second-line therapy for patients with so-
called treatment-resistant RRMS and with very active disease (Kappos, Bates 
et al. 2011). It lowers the risk of sustained progression of disability and reduces 
the rate of clinical relapse as well as the number of lesions detected by 
gadolinium-enhanced MRI (Polman, O'Connor et al. 2006).  
Inflammatory leukocytes use their VLA-4 molecule to dock to VCAM-1 (a 
vascular adhesion molecule expressed on cerebral endothelial cells) to 
extravasate out of blood vessels and reach the site of inflammation (Elices, 
Osborn et al. 1990). The mechanism of action of natalizumab is believed to be 
mediated through its ability to block the leukocytes’ VLA-4 molecule which in 
turn hinders them from escaping the blood circulation to enter the brain 
parenchyma (Baron, Madri et al. 1993).  
A serious complication of natalizumab treatment is the rare but dangerous 
reactivation of a latent JC-virus infection (Planas, Jelcic et al. 2011). While the 
exact connection of JC-virus reactivation and natalizumab treatment is still 
under discussion, many studies have detailed the changes in the composition 
of the white blood cells under natalizumab treatment (as reported on page 61).  
MS-patients treated with natalizumab show a lower leukocyte count in their 
cerebrospinal fluid (CSF) which is in keeping with the ability of natalizumab to 
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hinder leukocytes from crossing the blood brain barrier (Planas, Jelcic et al. 
2011). Because the number of CD4+ cells was found to be lower than the 
number of CD8+ cells in the CSF Planas and colleagues hypothesized that 
natalizumab has a more potent effect on CD4+ cells than it has on CD8+ cells 
(Stuve, Marra et al. 2006; Planas, Jelcic et al. 2011). 
Glycans on the cell surface 
Every cell in a multicellular organism expresses distinct glycans on its surface. 
Glycans are sugar residues that are attached to transmembrane glycoproteins 
and other molecules via post-translational modification. Glycosylation is the 
process of enzymatic addition of these sugars to proteins or peptides, which 
may change, modify or complete their function (Bertozzi and Rabuka 2009; 
Varki and Lowe 2009). The glycosylation of peptides within or on the surface of 
cells can, for example, mediate the specific recognition by other molecules as 
in the process of cell-cell interactions, cell development and differentiation, the 
adhesion of cells to certain tissues or the recognition of cells by pathogens and 
ligands (Varki and Lowe 2009).  
Some glycans are composed of sialic acids, which are nine-carbon acidic 
sugar residues located at the branching point of sugar chains. Their most 
common form is N-acetylneuraminic acid (also called Neu5Ac, NeuNAc, 
NeuAc, or NANA) (Varki and Lowe 2009). It is believed that sialic acids 
stabilise molecules, membranes and enzymes, modify the affinity of receptors 
and play a role in transmembrane signalling, growth and differentiation (Varki 
and Schauer 2009).  
For the sake of simplicity, in the following text 
“Neu5Ac/Gcα2,3Galβ1,4Glc(NAc)” is shortened to “α2,3 galactose residues”, 
“α2,6 galactose residues” stands for “Neu5Acα2,6Gal(NAc)-R”, and the 
designation “α1,2 fucose residues” is used for “Fucα1-2Gal-R.”  
Lectins 
Lectins are proteins that recognise and bind to glycans without catalysing or 
modifying the glycan. They are isolated from animals or plants and thus differ 
structurally from glycan-specific antibodies (Varki and Lowe 2009). Some 
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lectins specifically recognise the sialic acid linkage that is embedded in distinct 
sugar chains, and some other lectins bind specifically to glycans, that are not 
linked to sialic acid (Varki, Etzler et al. 2009). In our study we used the lectins 
MAL-II and SNA to detect sialylated α2,3 galactose residues and α2,6 
galactose residues, respectively, and UEA-I to mark α1,2 fucose residues.  
Aim of the study 
While the root cause of MS can still not be exactly pinned down, recent years 
have seen a rapid expansion of the knowledge of the cell types that accelerate 
or prevent the mechanism of the disease. In particular, Th1 and Th17 cells 
(both subsets of CD4+ T helper cells) are now thought to orchestrate the 
autoreactive immune reaction (Fletcher, Lalor et al. 2010). Understanding the 
roles of the individual cell types is crucial for tailoring new strategies for the 
alleviation and prevention of exacerbation in MS.  
It has been recently shown that the number of Th17 cells in the circulation of 
RRMS-patients increases during exacerbation and decreases under interferon 
beta treatment (Durelli et al, 2009). Further examples that illustrate treatment-
related changes in the blood cells of MS patients are lymphocytosis occurring 
under natalizumab treatment (Polman, O'Connor et al. 2006). Moreover, the 
suppression of IFN-γ secretion by CD4+ cells following exposure to IFN-β also 
demonstrates the influence that MS treatment has on the cells of the immune 
system (Skrzipek, Vogelgesang et al. 2011). Pro-inflammatory autoreactive 
cells that travel to the site of inflammation dock to certain vascular endothelium 
molecules to leave the blood vessels. Whether this docking process is 
influenced by a certain type of glycan on their surface has yet to be established 
(Sperandio, Gleissner et al. 2009).  
The purpose of the study was to document whether MS not only changes the 
quantitative composition of leukocytes but also whether it has an effect on the 
glycosylation of surface proteins. To this end, a flow cytometric analysis of the 
influence of MS and its immunomodulatory treatment on the glycosylation of 
white blood cells was performed. Cell type specific antibodies and lectins 
reactive with various different types of glycans (UEA-I, MAL-II, SNA and anti-
CD22) were used to mark the cell types and the glycans under study.  
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Patients, methods and material 
Peripheral blood mononuclear cells (PBMC) were taken from four different 
groups of trial subjects: RRMS patients treated with natalizumab, RRMS 
patients treated with interferon-β (IFN-β), and RRMS patients who were not 
receiving any immunomodulatory treatment and healthy volunteers, as control 
groups.  
Patients 
The study was carried out at the neurological outpatient department of the 
University Hospital in Tübingen. The participants included 
- 17 patients (10 women and 7 men) with relapsing-remitting multiple sclerosis 
(RRMS) who were treated with natalizumab (trade name: Tysabri®). Blood from 
the patients treated with natalizumab was drawn prior to each infusion of 
natalizumab. 
- 8 RRMS patients (6 women and 2 men) treated with interferon-β (trade 
names: Rebif®, Betaferon®, Avonex®).  
- 12 patients (8 women and 4 men) with RRMS who were not receiving any 
immunomodulatory therapy.  
- 14 healthy volunteers (5 women and 9 men).  
The patients had been diagnosed with multiple sclerosis according to the 
McDonald criteria (Polman, Reingold et al. 2005). None of the patients 
received any corticosteroids during the four weeks before the blood sample 
was obtained. All participants were informed and provided written consent 
according to the regulations of the local ethics committee. The project was 
approved by the Ethical Review Board of the Medical Department of the 
University of Tübingen on August 4, 2008.  
Cell isolation 
PBMC (peripheral blood mononuclear cells) were isolated through density 
centrifugation on lymphocyte separation medium (LSM). 7 to 10 mL of 
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peripheral blood was drawn from each patient using EDTA-tubes. The blood 
was diluted with PBS buffer to a final volume of 25 mL and then carefully 
layered onto 15 mL of lymphocyte separation medium in a 50 mL Falcon™ 
tube. The separation process was performed by centrifugation for 35 minutes 
at 20°C at 813x g (the equivalent of 2200 revolutions per minute with a rotor 
radius of 15 cm). The break of the centrifuge was switched off as a sudden 
stop of the centrifuge would have shaken up the individual layers in the 
Falcon™ tube. The PBMC located at the interface between the lymphocyte 
separation medium and the layer of PBS were carefully harvested into a fresh 
tube using a disposable pipette. This single cell suspension was washed twice, 
the first time in 30mL of PBS (20 minutes, 544x g, 20˚C) and the second time 
in 10 mL of PBS (8 minutes, 330x g, 20˚C).  
Extracellular staining of cells for flow cytometric analysis 
After the isolation process the cells were counted and checked for viability 
using a counting chamber and trypan blue. The cells were then transferred into 
the wells of a 96-well-plate at 500,000 cells per well. The cells were washed 
with 150 µL of FACS buffer (PBS 1x, 1% BSA, 0.02% NaN3).  
To prevent unspecific binding of the antibodies Fc-receptors were blocked by 
adding 50 µL of intravenous immunoglobulin (Ivig, Kiovig 1mg/mL; diluted 
1:50) and incubation for 15 minutes at 4˚C in darkness.  
Without any further washing step, the following antibodies and the lectins were 
added to the cells and left at 4˚C for 30 minutes in darkness: Anti-CD4 and 
anti-CD8 to mark T cells, anti-CD11c for dendritic cells, anti-CD14 for 
monocytes, and anti-CD20 for B cells. At the same time, the cells were stained 
with specific lectins and antibodies to compare their glycosylation patterns: 
SNA, MAL-II, UEA-I, and anti-CD22.  
As some of the antibodies were not labelled with a fluorescent dye but with 
biotin, the primary antibodies were stained with fluorescently labelled 
streptavidin after two washing steps with 150 µL of FACS buffer. Finally, the 
stained cells were washed two more times (to wash away the residual 
superfluous antibodies that might not have bound to the cells) and 
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resuspended in fixation buffer (10 mL of PBS and 280 µL of formaldehyde 
37%).  
T cell stimulation with PMA and ionomycin  
To augment the cellular production of IFN-γ, IL-4 and IL-17, 500,000 PBMC 
were incubated in 2 ng/mL PMA, 0.2 nmol/mL ionomycin, 0.2 nmol/mL 
monensin and complete RPMI in a 96-well flat bottom assay plate at a final 
volume of 200 μL at 37°C for 4 hours.  
Intracellular cytokine staining 
After stimulation with PMA/ionomycin, the cells were washed and stained, first 
extracellularly (as described on page 22), then intracellularly. Staining cells for 
intracellular antigens involves stabilising the cell membrane with formaldehyde 
and at the same time permeabilising the membrane with a detergent called 
saponin. To this end, cells were incubated in darkness for 60 minutes at 4˚C in 
100 μL of fixation/permeabilisation buffer (eBioscience). For the next washing 
step 200 μL of permeabilisation/wash buffer (eBioscience) were used to 
maintain the cell membrane’s permeability. Antibodies directed at intracellular 
antigens (anti-IFN-γ, anti-IL-4 and anti-IL-17) were added in the presence of 
permeabilisation buffer and incubated for 30 minutes at 4˚C in the dark.  
Intracellular FoxP3 staining 
Intracellular staining of the transcription factor FoxP3 is, in essence, performed 
the same way as intracellular cytokine staining with the exception that cell 
stimulation with PMA/ionomycin is not required.  
Flow cytometric analysis 
Cells were acquired on a CyAn Advanced Digital Processing High-
Performance Flow Cytometer and analysed with the Dako Summit software. 
The PBMC were gated based on forward and sideward scatter. The gate as it 
is drawn in the top panel of Figure 1 on page 30 includes activated and 
unactivated lymphocytes, dendritic cells and monocytes. 100,000 events in the 
lymphocyte gate were acquired for each analysis.  
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Buffers and solutions 
Complete RPMI: RPMI 1640 with HEPES and L-Glutamine, 10% FCS, 0.1% 
mercaptoethanol, 1% penicillin/streptomycin 
 
10% CuSO4-solution for incubator, solved in demineralised water 
 
Fixation solution: 280 µL of formaldehyde, 10 mL of PBS (phosphate buffered 
saline) 
 
FACS-buffer: 500 mL PBS, 5 g of BSA (bovine serum albumin), 1 mL NaN3 
 
Tools and reagents 
Tool/reagent manufacturer 
15 mL Tube CELLSTAR® Greiner bio-one, Frickenhausen 
50 mL Tube CELLSTAR® Greiner bio-one, Frickenhausen 
6-Mercaptoethanol, 50mM GIBCO® Invitrogen, Auckland, NZ 
70% Ethanol  
96-well Zellkulturplatten Flat-Bottom, 
mit Deckel, Falcon® 
BectonDickisonLabware, Franklin Lakes 
(USA) 
96-well Zellkulturplatten U-Bottom, mit 
Deckel, CELLSTAR® 
Greiner bio-one, Frickenhausen 
Auflichtmikroskop WilovertA A Hund, Wetzlar 
Bovine Serum Albumine (BSA) pH 7,0 PAA Laboratories GmbH, Pasching, 
Austria 
CO2 Water-Jacketed Incubator Nuaire US Autoflow 
CuSO4 SIGMA Chemical Co., St. Louis, USA 
CyAn Advanced Digital Processing (ADP) 
High-Performance Flow Cytometer 
Beckman Coulter, Inc., 4300, N. Harbor Blvd. 
Fullerton, CA 92835, USA 
DMSO (Dimethylsulfoxide) C2H6OS, 
Research Grade 
SERVA Electrophoresis GmbH, 
Heidelberg, Deutschland 
EDTA Merck KGaA, 64271 Darmstadt, Germany 
EDTA KE/9mL Monovette® Sarstedt, Nümbrecht 
Elektrische Eppendorf-Pipette „Easypet“ Eppendorf Vertrieb Deutschland 
Eppendorf-Cups  
Eppendorf-Pipetten (verschiedene 
Volumina und Ausführungen) 
Eppendorf Vertrieb Deutschland 
FACS CyAnTM ADP BeckmanCoulter GmbH,Krefeld, 
Deutschland 
FACS-Tubes (PP-Tubes 1,3mL 
8,55/44MM) 
Greiner bio-one, Frickenhausen 
Fetal bovine serum – heat inactivated, 
certified  
Cat# 10082-139, Invitrogen, Auckland, NZ 
Formaldehyd Merck Schuchardt OHG, 85662 
Hohenbrunn, Germany 
FoxP3 Fixation/Permeabilization Ebioscience, San Diego, CA 
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Concentrate  
FoxP3 Fixation/Permeabilization Diluent Ebioscience, San Diego, CA 
FoxP3 Permeabilization Buffer (10x) Ebioscience, San Diego, CA 
Gilson-Pipetten, Pipetman (verschiedene 
Volumina) 
Gilson, Inc.,  Middleton, USA 
IMDM (Iscove’s Modified Dulbecco’s 
Medium) 12440 (1x) & L-Glutamine, 
25mM HEPES GIBCO® 
Invitrogen, Auckland, NZ 
Interferon-β (betaferon®) Bayer AG 
51368 Leverkusen, Germany 
Ionomycin, Calcium Salt (2mM), 
Streptomyces conglobatus,Calbiochem® 
Merck KGaA, Darmstadt, Deutschland 
KHCO3 Merck KGaA, 64271 Darmstadt, Germany 
Kühl-/Gefrierkombination glassline Liebherr-Holding GmbH, Biberach 
KühlzentrifugeHeraeusMegafuge 1.0 R  Kendro Laboratory Products 
LSM 1077 Lymphocyte Separation 
Medium 
PAA Laboratories GmbH, Pasching, 
Austria 
MACS Multi Stand MiltenyiBiotecInc, Auburn (USA) 
MACS-Separation-Collums (LS, MS, LD) MiltenyiBiotecInc, Auburn (USA) 
Monensinsodiumsalt (2mM) Sigma-Aldrich Chemie GmbH, Steinheim, 
Deutschland 
NaN3 10% Merck 
Neubauer-Zählkammer, improved, Bright 
Line, 0,100mm Tiefe 
Glaswarenfabrik Karl Hecht KG 
NH4Cl SIGMA Chemical Co., St. Louis, USA 
Parafilm Pechiney, Plastic Packaging Menasha 
(USA) 
Pasteuerpipetten, Einweg, 3mL Carl Roth GmbH, Karlsruhe, Deutschland 
PBS: Dulbecco’s PBS (1x) without Ca& 
Mg, sterile 
PAA Laboratories GmbH, Pasching, 
Austria 
Penicillin/Streptomycin (10.000 U/mL 
Penicillin & 10.000 µg/mL Streptomycin)  
GIBCO® 
Invitrogen, Auckland, NZ 
Pipettenspitzen, verschiedeneGrößen Sarstedt, Nümbrecht 
PMA (Phorbol-12-myristate-13-acetate) 
1mg/mL (Purity 99,07%), Calbiochem® 
Merck KGaA, Darmstadt, Deutschland 
S1-Biogard-Hood, Modell B60-112 The Baker Co. Inc., Sanford, Maine 
Safety-Multifly®-Set Sarstedt, Nümbrecht 
Serologische Pipette costar® 
verschiedene Volumina 
CorningIncorperated, Corning (USA) 
Serologische Pipette Falcon® 
verschiedene Volumina 
BectonDickisonLabware, Franklin Lakes 
(USA) 
Spritze, 2mL, BD PlastipakTM BectonDickison, Madrid (Spain) 
Sterilisator, A16/50, BJ 1922, Inh. 14,6ltr WEBECO, Selmsdorf, Deutschland 
Summit (FACS software) Dako Colorado, inc., 8450 Innovation 
Drive, Fort Collins, CO 80525, USA 
TrypanBlue Solution (0,4%) SIGMA Chemical Co., St. Louis, USA 
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Vortex Genie 2TM Bender &Hobein AG, Zürich, Schweiz 
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Antibodies and lectins 
Antibody/ 
lectin 
 
 
clone fluores-
cence 
concen-
tration1
Cat# 
 
manufacturer 
Anti-CD25 BC96 FITC 12,5µg/mL 302603 Biolegend 
Anti-CD11c B-ly6 apc 1.25 µg/mL 559877 BD Bioscience 
Anti-CD14 61D3 apc 1.25 µg/mL 17-0149-
71 
eBioscience 
Anti-CD20 L27 PerCP 1/50 345794 BD Bioscience 
Anti-CD4 RPA-T4 APC 0.25 µg/mL 17-0049-
42 
eBioscience 
Anti-CD69 FN50 FITC 25µg/mL 310904 Biolegend 
Anti-CD8 RPA-T8 APC 1/100 555369 BD-
Biosciences 
Anti-FoxP3 PCH101 PE 2.5 µg/mL 12-4776-
42 
Ebioscience 
Anti-IFN-γ 4SB3 PE 2.5 µg/mL 12-7319-
41 
Ebioscience 
Anti-IL-17  BL168 PE 1/100 512305 Biolegend 
Anti-IL4 8D4-8 PE 2.5 µg/mL 12-7049-
41 
Ebioscience 
anti-CD22 HIB22 FITC 1/75 F-5546 sigma 
Ivig   10mg/mL  Kiovig 
MAL-II  biotin. 10 µg/mL B-1265 Vector 
Normal rat-
Serum 
   24-5555-
94 
Ebioscience 
SNA   biotin. 6.66 μg/mL  B-1305 Vector 
Strept-avidin  Pacific-Blue 10 µg/mL S11222 Invitrogen 
UEA-I BAL-
22012 
biotin. 4.44 µg/mL B-1065 Vector 
                                            
1
  Concentration here indicates the concentration at which the antibody was 
used. The dilution at which the antibody from the vial was diluted is only given in 
cases where the manufacturer withheld the antibody concentration of the original vial.  
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Statistical analysis 
The statistical analysis of the data was performed with IBM® SPSS® Statistics 
version 19. The non-parametric Mann-Whitney-U-test was used to detect 
statistical significance between two different groups. A p-value of <0.05 was 
considered significant.  
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Results  
FACS analysis of PBMC 
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Figure 1 FACS analysis of human peripheral blood cells stained with 
fluorescent antibodies directed against CD4, CD8, CD11c, CD14 and CD20. At 
the same time the cells were also stained with MAL-II, SNA and UEA-I that 
bind to α2,3-galactose residues, α2,6-sialylic acid and α1,2-linked fucose 
residues respectively. The graph at the top shows PBMC in the forward and 
sideward scatter. The gate was drawn around all PBMC to include 
lymphocytes (CD4+, CD8+ and CD20+), dendritic cells (CD11c+), and 
monocytes (CD14+). The analysis of CD4+ cells shows the existence of a 
CD4low and a CD4high population, both of which were analysed for their 
respective sialylation or fucosylation (boxes a-f). Boxes g-i show the sialylated 
and fucosylated fraction of CD8+ cells, boxes j-l show the 
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sialylated/fucosylated fraction of CD11c+ cells, boxes m-o show the 
sialylation/fucosylation of CD14+ cells and boxes p-r show the 
sialylation/fucosylation of CD20+ cells. 
 
 
Distribution of leukocyte subsets under the influence of 
natalizumab and interferon-β treatment 
 
Figure 2 shows the percentages of various leukocyte subsets within the PBMC 
population in RRMS patients receiving natalizumab, RRMS patients treated 
with interferon-β, untreated RRMS patients and healthy controls. The bars 
indicate the means in % while the whiskers represent the standard error of the 
mean (SEM). The horizontal lines with the p-value on top indicate statistical 
significance between the bars that they connect.  
Natalizumab treatment was associated with a rise in relative numbers of 
CD4high cells, cytotoxic T cells (CD8+) and B cells (CD20+).  Quite the 
contrary, the percentage of CD4low cells was decreased under natalizumab. 
IFN-β treatment was associated with an increased portion of cytotoxic T cells 
(CD8+). No significant differences were noted among dendritic cells (CD11c+) 
and monocytes (CD14+).  
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Figure 3 shows the portions of all CD4+ cells in RRMS patients receiving 
natalizumab and IFN-β, and in control groups. The portion of CD4+ cells did 
not differ significantly between groups.  
Table 1 shows the distribution of various leukocyte subsets in percent of all 
PBMC (peripheral blood mononuclear cells). The numbers are displayed as 
means ± SEM. * n=12, ** n=18 
 untreated 
RRMS 
natalizumab IFN-β healthy control 
n 8 17 8 14 
CD4hig
h 
28.3 ± 5.5 40.4 ± 1.6 35.0 ± 3.1 33.3 ± 2.3 
CD4low 23.9 ± 4.9 10.5 ± 1.1 18.1 ± 4.1 17.2 ± 2.0 
CD4+ 50.9 ± 2.7* 50.7 ± 1.2** 53.1 ± 3.1 50.6 ± 3.2 
CD8+ 9.6 ± 1.3 14.9 ± 1.2 16.4 ± 2.4 13.4 ± 1.2 
CD11c+ 20.5 ± 4.5 12.5 ± 1.1 15.8 ± 4.0 15.0 ± 1.4  
CD14+ 18.4 ± 3.6 11.5 ± 1.1 14.4 ± 3.9 13.6 ± 1.2 
CD20+ 7.2 ± 1.5 17.3 ± 1.6 6.8 ± 1.4 7.1 ± 1.0 
 
Natalizumab treatment was associated with a larger 
percentage of unactivated T helper cells (CD4high) cells, 
but with a smaller percentage of activated CD4 T cells 
(CD4low) 
RRMS-patients treated with natalizumab had a larger percentage of non-
activated CD4high cells and a smaller percentage of activated CD4low cells.  
The fraction of non-activated T cells (CD4high cells) was increased by 42% in 
RRMS-patients receiving natalizumab compared to RRMS-patients under no 
immunomodulatory treatment (p=0.036). Compared to healthy controls, the 
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fraction of non-activated T cells (CD4high cells) was increased by 21% in 
RRMS-patients receiving natalizumab treatment (p=0.032). Conversely, the 
percentage of activated CD4+ cells (CD4low cells) in RRMS patients under 
natalizumab treatment was by 56% smaller than in untreated RRMS-patients 
(p=0.006), and by 39% smaller than in healthy controls (p=0.004) (Figure 2 and 
Table 1).  
The percentage of B cells was increased in natalizumab-
treated RRMS patients  
With an increase of 140% the percentage of B cells (CD20+) more than 
doubled under natalizumab therapy compared to RRMS without treatment 
(p=0.001) (Figure 2 and Table 1).  
Natalizumab- and IFN-β-treatment were both associated with 
an increase in the percentage of cytotoxic T cells in 
RRMS patients 
The percentage of cytotoxic T cells (CD8+ cells) was increased by 54% under 
natalizumab-treatment (p=0.007) and by 70% under interferon-β-treatment 
(p=0.017) compared to RRMS patients under no immunomodulatory therapy. 
Besides, healthy volunteers also showed greater numbers of CD8+ cells (39 % 
higher, p=0.036) than untreated RRMS patients (Figure 2 and Table 1).  
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Sialylation and fucosylation of various immune cells  
FACS analysis of MAL binding to leukocyte subsets in 
natalizumab- and IFN-β-treated patients 
 
Figure 4 (This figure also includes the diagram on the next page) shows a 
FACS analysis of lymphocytes, dendritic cells and monocytes and their binding 
to MAL. Cells obtained from natalizumab-treated and IFN-β-treated RRMS 
patients, from untreated RRMS-patients and from healthy controls are 
compared. IFN-β treatment was associated with a lower binding affinity of MAL 
to unactivated T cells (CD4high).  
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Table 2 shows the percentage ± SEM of cells expressing α2,3 sialylated 
galactose residues within each leukocyte subset (CD4low, CD4high, CD8+, 
CD20+, CD11c+ and CD14+ cells) from RRMS-patients treated with 
natalizumab, RRMS-patients treated with IFN-β, untreated RRMS-patients and 
healthy donors, respectively . The number of cases “n” is given underneath 
each cell type. 
 Natalizumab IFN-β untreated 
RRMS 
healthy 
donors 
CD4low 7.0 ± 0.9 4.4 ± 0.8 9.0 ± 3.4 7.1 ± 1.2 
n 17 8 8 14 
CD4high 7.3 ± 0.7 3.4 ± 1.3 17.8 ± 7.7 6.0 ± 0.8 
n 17 8 8 14 
CD8+ 8.7 ± 1.0 9.0 ± 1.7 13.8 ± 5.9 8.4 ± 1.3 
n 15 8 8 14 
CD20+ 10.4 ± 1.5 8.2 ± 1.7 27.3 ± 8.1  16.9 ± 2.7 
n 16 6 6 13 
CD11c+ 8.7 ± 1.0 7.3 ± 2.0  16.4 ± 6.5 13.7 ± 5.4 
n 16 8 8 14 
CD14+ 9.5 ± 1.4 11.4 ± 4.6  18.1 ± 7.1 12.0 ± 2.2 
n 16 8 8 14 
  
Figure 5 shows the percentages of various MAL+ leukocytes. The horizontal 
lines indicate statistical significance. Note the small portion of CD4highMAL+ 
cells and CD20+MAL+ cells under natalizumab and IFN-β treatment. 
 
INF-β treatment was associated with a lower amount of α2,3-
galactose sialylation on non-activated CD4high cells 
IFN-β treatment was associated with a decrease in α2,3-galactose sialylation 
of non-activated CD4high cells. Specifically, the proportion of unactivated T 
helper cells that bind to MAL was 81% lower in IFN-β-treated patients than in 
untreated RRMS patients (p=0.019).  
 Natalizumab treatment was associated with a lower amount of 
α2,3-galactose sialylation on B cells 
Double staining with anti-CD20 and the lectin MAL showed that compared to 
healthy controls the portion of CD20+ cells that bound to MAL was 51% lower 
in RRMS patients under IFN-β treatment (p=0.065) and 39% lower in RRMS 
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patients under natalizumab (p=0.034). The percentage of MAL+ B cells in 
natalizumab- and IFN-β-treated patients was also smaller than in untreated 
patients, although the p-values did not show significant differences (p=0.133 
between natalizumab-treated patients and untreated patients and p=0.107 
between IFN-β-treated patients and untreated patients) (Figure 5 and Table 2 
on page 37).  
 
 
 
Percentages of SNA+ leukocyte subsets in natalizumab- and 
IFN-β-treated RRMS patients 
Table 3 The results are presented as percentage ± SEM of cells expressing 
α2,6-sialylic acid within each leukocyte subset (CD4low, CD4high, CD8+, 
CD20+, CD11c+ and CD14+ cells) from RRMS-patients treated with 
natalizumab, RRMS-patients treated with IFN-β, untreated RRMS-patients and 
healthy donors, respectively. The number of cases “n” is given underneath 
each cell type. 
 Natalizumab IFN-β untreated 
RRMS 
healthy 
donors 
CD4low 99.6 ± 0 .2 98.9 ± 0.6 97.7 ± 0.9 99.0 ± 0.4 
n 17 8 10 13 
CD4high 99.6 ± 0.2 98.5 ± 1.1 98.2 ± 0.7 99.5 ± 0.14 
n 17 8 11 14 
CD8+ 99.6 ± 0.2 96.3 ± 1.3 98.9 ± 0.4 90.6 ± 7.4 
n 16 7 11 11 
CD20+ 99.4 ± 0.2 98.3 ± 0.4 99.4 ± 0.3 99.4 ± 0.1 
n 17 6 10 13 
CD11c+ 99.3 ± 0.2 98.0 ± 1.2 99.2 ± 0.4 99.0 ± 0.2 
n 16 7 11 13 
CD14+ 99.4 ± 0.3 96.6 ± 0.9 99.0 ± 0.3 98.9 ± 0.3 
n 16 8 11 13 
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Figure 6 Percentage of SNA+ cells of the respective leukocyte subset. The 
horizontal lines connect bars that show significant differences. The bar charts 
reflect that SNA bound abundantly to all sorts of immune cells within our scope 
from all groups of trial subjects. 
 
All leukocytes expressed plentiful amounts of α2,6-linked 
galactose 
All the leukocyte subsets within our scope expressed α2,6-sialylic acid 
abundantly. The presence of RRMS and the type of therapy had no or only a 
minor influence on the binding capacity of those cells (Figure 6 and Table 3).  
 
Percentages of UEA+ leukocyte subsets in natalizumab- and 
IFN-β-treated patients 
Table 4 shows the percentage ± SEM of cells expressing α1,2-linked fucose 
residues within each leukocyte subset (CD4low, CD4high, CD8+, CD20+, 
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CD11c+ and CD14+ cells) from RRMS-patients treated with natalizumab, 
RRMS-patients treated with IFN-β, untreated RRMS-patients and healthy 
donors, respectively. The number of cases “n” is given underneath each cell 
type 
 Natalizumab IFN-β untreated 
RRMS 
healthy 
donors 
CD4low 5.9 ± 0.9 5.8 ± 2.1 5.3 ± 1.4 5.0 ± 0.9 
n 17 8 8 14 
CD4high 3.8 ± 0.3 4.8 ± 1.6 4.0 ± 1.4 4.4 ± 0.5 
n 17 8 8 14 
CD8+ 4.8 ± 0.5 4.4 ± 1.0 12.1 ± 7.0  4.6 ± 0.5 
n 15 7 8 12 
CD20+ 12.8 ± 2.5 12.5 ± 5.6 44.3 ± 9.9 27.5 ± 6.2 
n 16 6 6 13 
CD22+ 24.2 ± 2 51.3  ± 9.4 33.9 ± 5.6 53.7 ± 6.4 
n 14 4 9 11 
CD11c+ 7.9 ± 0.8 8.6 ± 2.8 16.7 ± 6.8 12.4 ± 3.8 
n 15 8 7 14 
CD14+ 8.4 ± 1.3 7.9 ± 3.6 14.1 ± 6.2 6.9 ± 0.7 
n 16 8 8 14 
 
Figure 7 Percentage of UEA+ cells of the respective leukocyte subset. The 
horizontal lines connect bars that differ significantly from each other. 
Natalizumab and IFN-β treatment were associated with a lower binding 
capacity for UEA in B cells (CD20+ cells).  
B cells expressed a smaller amount of α1,2-linked fucose in 
response to natalizumab and interferon-β treatment 
UEA-I was used to asses the expression of α1,2-linked fucose residues. 
Among the various leukocyte subsets only B cells seemed to change their 
bindig capacity of UEA-I in response to natalizumab- and IFN-β treatment: 
Both IFN-β and natalizumab treatment were associated with a lower 
expression of α1,2-linked fucose residues on CD20+ cells.   
The portion of CD20+UEA+ cells decreased by 53% under natalizumab 
treatment compared to healthy controls (p=0.029) and by 71% compared to 
untreated RRMS patients (p=0.025).  
Similarly, the percentage of UEA+CD20+ B cells in IFN-β-treated patients was 
72% smaller than in RRMS patients without immunomodulatory therapy 
(p=0.016) (Table 4 and Figure 7 on pages 40 and 41). 
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The α1,2-fucosylation of CD22+ cells roughly corresponded to the α1,2-
fucosylation of CD20+ cells. A notable exception to this was that IFN-β 
treatment did not seem to decrease the UEA binding capacity of CD22+ cells 
(Figure 7 on page 41).  
CD20+ cells and CD11c+ cells express CD22 on their surface  
Table 5 shows the percentage ± SEM of CD20+ cells and CD11c+ cells 
expressing CD22 on their surface. “n” is given underneath each cell type to 
designate the number of cases.  
 Natalizumab IFN-β untreated 
RRMS 
healthy 
donors 
CD20+ 88.5 ± 1.6 91.6 ± 1.4 89.6 ± 2.3  94 ± 0.7 
n 10 5 9 13 
CD11c+ 1.2 ± 0.1 0.5 ± 0.2 0.4 ± 0.2 0.3 ± 0.1 
n 15 8 10 14 
 
 
Figure 8 Anti-CD22 bound to B cells (CD20+ cells) and to dendritic cells 
(CD11c+ cells).  
The aim of this FACS analysis was to document which cell types express the 
surface molecule CD22. It turned out that anti-CD22 bound to CD20+ cells and 
(to a much lesser extent) to CD11c+ cells (Figure 8) but not to the other cell 
types under study (data not shown).  
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Distribution of CD4 subsets 
Distribution of Th1 cells, Th2 cells, Th17 cells and regulatory T 
cells in healthy volunteers 
 
Figure 9 displays the frequencies of T cell subsets (Th1, Th2, Th17 and 
regulatory T cells) in percent of CD4+ cells in healthy donors, measured by 
FACS analysis 
The percentage of Th1 cells was larger in natalizumab-treated 
patients than in healthy volunteers 
Table 6 shows the percentage ± SEM of CD4+ cells expressing IFN-γ, IL-4 
and IL-17 in natalizumab-treated RRMS patients and healthy controls. The 
expression of the transcription factor FoxP3 was assessed in IFN-β-treated 
RRMS patients and in treatment-naive RRMS patients in addition. The number 
of cases “n” is given underneath each row.  
 natalizumab healthy control 
IFN-γ+ of CD4+ 25.3 ± 3.5 13 ± 3.5 
n 7 10 
IL-4+ of CD4+ 6.1 ± 1 5.1 ± 1.1 
n 7 10 
IL-17+ of CD4+ 1.9 ± 0.3 1.2 ± 0.2 
n 7 5 
     
 natalizumab IFN-β untreated  healthy c. 
FoxP3+ of CD4 4.9 ± 0.8 5.8 ± 1.5 3.5 ± 0.8 3.2 ± 0.7 
n 9 4 5 6 
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Figure 10 shows the percentage of the particular T helper subset among all 
CD4+ cells, comparing healthy volunteers to natalizumab-treated patients.  
PBMC were stained for CD4 and intracellular, subset-specific markers. The 
aim was to assess possible differences between natalizumab-treated patients 
and healthy volunteers. The portion of Th1 cells (IFN-γ secreting CD4+ cells) 
under natalizumab was 94% larger than healthy controls (p=0.005) (Figure 10).  
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Sialylation and fucosylation of CD4+ Th1, Th2, Th17 and 
regulatory T cells in healthy volunteers 
Th2 cells had the highest binding capacity to MAL 
 
Figure 11 FACS analysis of MAL binding to Th1, Th2, Th17 cells and 
regulatory T cells 
 
Figure 12 While 62% of Th2 cells were MAL+, other T cell subsets expressed 
significantly fewer binding sites for MAL 
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Table 7 displays the percentage ± SEM of CD4+ T cell subsets (Th1, Th2, 
Th17 and regulatory T cells) expressing binding sites for MAL 
 Th1  
(IFN-γ+)  
Th2  
(IL-4+) 
Th17  
(IL-17+)  
Tregs  
(FoxP3+) 
% MAL+ 7.6 ± 1.2 62.1 ± 5.0 15.3 ± 4.3 4.9 ± 0.7 
n 10 10 9 10 
 
MAL was used as a marker to assess the α2,3-sialylation on T cell subsets. It 
turned out that significantly more Th2 cells expressed binding sites for MAL, 
than did Th1 cells (p=0.000), Th17 cells (p=0.000) and Tregs (p=0.000).  
UEA binding to Th2 cells was higher than in other T helper 
subsets 
 
Figure 13 Flow cytometry analysis of ulex europaeus lectin (UEA) sialylation of 
Th1, Th2, Th17 and regulatory T cells. 
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Figure 14 shows the percentage of T cell subsets that show reactivity to UEA 
as measured by FACS analysis. Horizontal bars designate statistical 
significance 
Table 8 displays the percentage ± SEM of CD4+ T cell subsets (Th1, Th2, 
Th17 and regulatory T cells) expressing binding sites for UEA 
 Th1  
(IFN-γ+) 
Th2  
(IL-4+) 
Th17  
(IL-17+) 
Tregs  
(FoxP3+) 
% UEA+ 8.0 ± 1.4 59.4 ± 5.4 16.2 ± 5.7 16.9 ± 3.5 
n 10 10 9 10 
 
PBMC were stained for CD4 and markers specific for T helper subsets. UEA 
was used to assess their α1,2-fucosylation.  
Similarly to the MAL+ T cell subsets, there were more UEA+Th2 cells than 
UEA+Th1 cells (p=0.000), UEA+Th17 cells (p=0.001) and Tregs (p=0.000). 
Also, the difference between Th1 and Tregs is p=0.04.  
All CD4 T cell subsets showed a high affinity to SNA 
Table 9 displays the percentage ± SEM of CD4+ T cell subsets (Th1, Th2, 
Th17 and regulatory T cells) expressing binding sites for UEA 
 Th1  
(IFN-γ+) 
Th2  
(IL-4+) 
Th17  
(IL-17+) 
Tregs  
(FoxP3+) 
% SNA+ 95.9 ± 2.3 97.2 ± 1.5 87.7 ± 7.1 88.3 ± 5 
n 10 9 6 6 
P=0.000 
P=0.000 
P=0.000 
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Figure 15 shows the percentage of T cell subsets that show reactivity to SNA 
as measured by FACS analysis 
The assessment of α2,6-sialylation of CD4+ T cell subsets showed that SNA 
bound abundantly to all T cell subsets (Figure 15). This phenomenon could 
also be observed in other types of leukocytes (Figure 6 on page 39).  
In summary, Th2 cells (IL-4 secreting CD4+ cells) showed a marked affinity to 
MAL-II and UEA-I that was unparalleled by any other T cell subset under study.  
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Discussion 
It has been observed that in the course of MS some cell types expand or 
decrease in number while some other cell types change or lose their function 
and characteristics. For example, the number of circulating Th17 cells 
increases during an exacerbation of MS, and decreases under interferon 
treatment (Durelli, Conti et al. 2009). An example for cells that alter their 
properties in the course of an autoimmune disease is regulatory T cells. 
Regulatory T cells occur in the same frequency in MS patients as they do in 
healthy controls, but their immunosuppressive function is impaired in MS 
patients (Feger, Luther et al. 2007). Our motivation was to find out if the 
treatment of RRMS with natalizumab and IFN-β are associated with altered 
sialylation/fucosylation patterns of immune cells. Further experiments could 
then show if the changes in sialylation and fucosylation go along with functional 
changes in these cells.  
Our data show that natalizumab and IFN-β treatment were associated with 
both changes in sialylation/fucosylation and frequency of certain cell types.  
Cell types 
CD4+ cells 
CD4low and CD4high cells  
As Figure 1 on page 30 shows FACS analysis revealed two distinct 
populations of CD4 cells among the PBMC: One that expresses CD4 at a high 
level and one that downregulates its CD4 antigen. This brought up the question 
whether the activation state of CD4+ cells influences the way they up- or 
downregulate their CD4-antigen. To obtain a sample of activated cells human 
PBMC were stimulated with PMA and ionomycin. Double staining for CD69 (an 
activation marker) and CD4 showed that a considerable portion of activated 
CD69+CD4+ cells in the lymphocyte gate sends out a weaker CD4 signal than 
unstimulated cells (Figure 16). Consequently, it can be inferred that CD4high 
cells are non-activated CD4+ cells and CD4low cells are activated CD4+ cells.  
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Figure 16 shows unstimulated CD4 T cells that express CD4 at a high level 
(upper panels) and stimulated cells expressing CD4 at a lower level. The 
broken lines illustrate the difference in brightness of CD4 expression between 
the stimulated and unstimulated lymphocytes. PBMC from the lymphocyte gate 
were used for analysis.  
Th1 cells  
FACS analysis of PBMC obtained from healthy donors revealed a frequency of 
Th1 cells of approximately 13% of CD4+ cells. This corresponds to the 
numbers we obtained from literature, where Chi, Xu and colleagues (2010) 
report that approximately 16% of the CD4+ cells in patients with neurological 
disease other than demylinating diseases are Th1 cells.  
In our study we saw a larger percentage of CD4+IFN-γ+ cells in natalizumab-
treated RRMS patients which points to a higher Th1 frequency in that group 
(Figure 10). Similarly, a higher IFN-γ-production in RRMS patients in proportion 
to disease activity has been reported (Frisullo, Nociti et al. 2008).  
Th17 cells 
IL-17 showed a dim signal in FACS analysis (Figure 13), which other authors 
also report (Chi, Xu et al. 2010). In our study, the frequency of CD4+IL-17+ 
Th17 cells among CD4+ cells was 1.2 ± 0.2% (Figure 10, Table 6), which is 
close to what we found in literature: 1.02 ± 0.37% (Chi, Xu et al. 2010). 
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Regulatory T cells 
According to our analysis CD4+FoxP3+ regulatory T cells make up 3.2-5.8% of 
peripheral CD4+ cells in humans (Table 6 on page 44), which is close to the 5-
10% that have been reported in literature (as reviewed by Takahashi, Kuniyasu 
et al. 1998). The frequencies of regulatory T cells in our study do not vary 
significantly between groups (Figure 10). Therefore, our data are in line with 
previous findings which report that MS is not associated with an altered portion 
of peripheral regulatory T cells (Feger, Luther et al. 2007).  
CD20+ cells (B cells) 
The percentage of B cells in natalizumab-treated patients more than doubled 
the percentage of B cells in the untreated RRMS control group (Table 1, Figure 
2). This phenomenon will be discussed on page 61.  
CD8+ cells (cytotoxic T cells)  
The portion of CD8+ cells was increased 1.5-fold in RRMS patients treated 
with natalizumab compared to untreated RRMS patients (Table 1, Figure 2). 
This has also been observed by Putzki and Baranwald (2010) who report a 
1.7-fold increase of CD8+ cells under natalizumab treatment.  
CD14+ cells (monocytes) 
Although observations to the contrary have also been made (Polman, 
O'Connor et al. 2006), natalizumab therapy seems to decrease the number of 
monocytes in RRMS-patients (Skarica, Eckstein et al. 2011). Our data show an 
insignificant trend toward this direction (Figure 2 on page 31). 
 
Sialylation and fucosylation 
α2,3-linked galactose residues detected with MAL-II 
Maackia amurensis lectin II (MAL-II) is a hemoagglutinin and therefore it is 
sometimes also called Maackia amurensis hemagglutinin (MAH), depending on 
which vendor it is bought from (Geisler and Jarvis, 2011). It serves as a 
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detection tool for α2,3-linked sialic acids, in particular Siaα2-3Galβ1-3(±Siaα2-
6)GalNAc (Geisler and Jarvis, 2011; Wang and Cummings 1988).  
The exact role of α2,3-linked sialic acids on the surface of immune cells still 
needs to be clarified. It was shown that the molecule responsible for L-selectin 
mediated leukocyte interaction (PSGL-1, P-selectin glycoprotein ligand-1) is 
dependent on the α2-3-sialyltransferase (ST3Gal IV) (Sperandio, Frommhold 
et al. 2006). However, the actual α2,3-sialylation carried out by α2-3-
sialyltransferase (ST3Gal-IV) is not needed for the capture and rolling of 
leukocytes, as was shown in an experiment involving high endothelial cells of 
Peyer's patch (Sperandio, Frommhold et al. 2006). Thus, it is still not entirely 
clear whether α2,3-linked sialic residues on leukocytes play a role in 
chemokine-mediated cell adhesion and extravasation (Sperandio, Gleissner et 
al. 2009).  
We found that IFN-β had similar effects on the expression of α2,3-linked sialic 
acid on both B cells and unstimulated T cells (CD4high cells): In our study IFN-
β treatment of RRMS-patients was associated with a decreased expression of 
α2,3-linked sialic acid on unstimulated T cells and a trend toward that a lower 
portion of α2,3 sialylated B cell (Figure 5 on page 37). By way of contrast, 
natalizumab treatment did not seem to have any significant effect on the α2,3 
sialylation of most kinds of immune cells within our scope. In B cells, there was 
a slightly smaller portion of α2,3 sialylated B cells under natalizumab 
treatment, but only when compared to healthy controls.  
Furthermore, a clear increase in α2,3-linked sialic acid expression was noted in 
the Th2 cells of healthy donors, compared to other T helper subsets (see page 
46). The fact that the focus of the pathogenesis of MS lies on Th1 and Th17 
cells rather than on Th2 cells makes it difficult to draw a conclusion concerning 
the α2,3-sialylation of Th2 cells and autoimmune diseases. To evaluate the 
role of α2,3-sialylation on T helper cells more research is necessary.   
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α2,6-linked galactose detected with SNA 
SNA (sambucus nigra) is a lectin isolated from elderberry. It is highly specific 
for α2,6-linked galactose, which makes it an eligible tool to detect these distinct 
sugar chains on the cell surface (Shibuya, Goldstein et al. 1987). 
The current data show that all the immune cells under study were highly 
reactive with SNA (as shown on page 39). To rule out the possibility of 
unspecific binding because of too high concentrations of SNA (in spite of the 
use of intravenous immunoglobulin as an Fc-receptor block) we performed 
titration studies for SNA (Figure 17). It turned out that lower concentrations of 
SNA led to a dimmer signal in FACS analysis but did not decrease the 
percentage of cells that were reactive with SNA. Following this pilot experiment 
SNA was used at a concentration of 6.66 μg/mL for assessing the α2,6-
sialylation of PBMC.  
 
Figure 17 Titration studies of SNA to rule out unspecific binding of SNA to 
CD4+ and CD4- lymphocytes. The top panels show the SNA-binding CD4- and 
CD4+ lymphocytes with the respective SNA-concentrations indicated at the 
bottom. The bottom panels show the SNA-signal of CD4+ lymphocytes. With 
smaller concentrations of SNA the brightness of the SNA-signal is reduced. 
Nevertheless, no change in the percentage of SNA+ cells could be observed. 
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It has been suggested that several lectins including SNA are toxic to cells 
(Batisse, Marquet et al. 2004; Franz, Frey et al. 2006). However, Malagolini, 
Chiricolo and colleagues (2009) conducted FACS analysis studies and 
dismissed the allegedly toxic effect of SNA as insignificant. Even so, we often 
noticed a drop in cell count after we stained PBMC with fluorescent SNA. This 
phenomen was not observed after incubation with MAL or UEA instead. 
Consequently, we sought to find out if the presence of SNA really affected our 
cells more than the exposure to other lectins. FACS analysis is a viable 
method to determine the size and granularity of cells. Our rationale was that if 
cells shrink as they undergo apoptosis, smaller forward scatter values in FACS 
analysis would point to the typical apoptosis-dependent cell shrinkage (Franz, 
Frey et al. 2006).  
Our PBMC did in fact show an altered FACS profile after exposure to SNA for 
30 minutes (Figure 18). The population of dead cells (in the bottom left hand 
corner of the FACS diagram) expanded to greater numbers on both the 
forward and the sideward scatter scale and their percentage more than 
doubled (data not shown). In contrast to the “dead cell population”, the 
lymphocyte population that had been stained with SNA did not show any 
decrease in its forward scatter value but stayed in the same position. The 
border between “dead cells” and lymphocytes seemed to be less demarcated 
in the lower bottom corner of the FACS diagram on the left. This implies that 
SNA exposure results in a larger percentage of dead cells in the PBMC 
population but does not change the size and granularity of those cells that 
could withstand the cytotoxic effects of SNA.  
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Figure 18 FACS analysis of size (forward scatter, FS) and granularity 
(sideward scatter, SS) of PBMC exposed to SNA for half an hour (left) and 
MAL (centre) and UEA (right) for comparison. Note the expansion of the 
population of dead cells (in the bottom left hand corner; see arrow) following 
incubation with SNA. 
It has been shown that several cell types, including human neutrophils, react 
strongly with SNA when they undergo apoptosis (Malagolini, Chiricolo et al. 
2009). This finding is in line with the results of our experiment, in which dead 
PBMC showed strong reactivity with SNA (Figure 19). On the other hand, 
Batisse, Marquet et al. (2004) confirmed that apoptotic cells down-regulate 
their binding sites for both MAL and SNA. It should be noted, however, that 
Batisse et al. performed their experiment with a myelomonocytic cell line 
derived from a patient who had histiocytic lymphoma, whereas we focused on 
PBMC from patients with RRMS and healthy donors. In contrast to what 
Batisse et al. report, in our experiment SNA bound to lymphocytes to the same 
extent as it bound to dead PBMC (Figure 19). We cannot rule out the 
possibility that there were a number of dead or apoptosing lymphocytes in the 
lymphocyte gate because we did not use a marker for apoptosis, such as 
annexin-V.  
In our experiment the reactivity of PBMC with MAL and UEA is clearly weaker 
than the reactivity with SNA. “Dead cells” from the lower left hand corner of the 
FACS diagram and lymphocytes show a high affinity for SNA alike (Figure 19 
and Figure 20).  
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Figure 19 This FACS analysis shows that almost all dead PBMC (upper panel) 
and almost all lymphocytes (lower panel) express plenty of binding sites for 
SNA.  
55 
 
 
Figure 20 MAL and UEA show poorer reactivity with lymphocytes than does 
SNA. MAL and UEA show some affinity to dead cells (second and fourth 
panels) but not as much as SNA does. 
To answer the question whether the putative cytotoxic effects of SNA (Batisse, 
Marquet et al. 2004) account for the unusual configuration of SNA-exposed 
PBMC in the FS SS diagram we compared our SNA-concentration to the 
results published by another research group. Batisse et al. (2004) demonstrate 
the dose-dependent cytotoxic effect of SNA on lymphocytes by assessing the 
percentage of apoptotic and necrotic cells with the help of an annexin V/PI 
assay. Their results point to a clear dose dependent cytotoxicity of SNA with 50 
μg/mL resulting in an apopotosis rate of 12%, and 10 μg/mL of SNA leading to 
5% apoptotic cells after 45 minutes (Batisse, Marquet et al. 2004). The SNA-
concentration that we used for our experiments, namely 6.66 μg/mL, is close to 
the concentration that showed only very small numbers of apoptotic and 
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necrotic cells in the experiment performed by Batisse, Marquet et al. (2004): In 
their experiment an SNA-concentration of 5 μg/mL lead to only 3% apoptotic 
cells and 1% necrotic cells (Batisse, Marquet et al. 2004).  
To find out whether our SNA-concentration of 6.66 μg/mL has a deleterious 
impact on PBMC we compared the FS SS diagrams of PBMC incubated for 30 
minutes with decreasing concentrations of SNA (Figure 21). Again, PBMC 
exposed to 6.66 μg/mL of SNA for 30 minutes showed a more marked fraction 
of dead cells in the FACS diagram than cells incubated with smaller 
concentrations of SNA. However, the overall percentage of dead cells showed 
no correlation with the amount of SNA that had been applied.  
It can therefore be concluded that the SNA-concentration of 6.66 μg/mL might 
be somewhat toxic to PBMC but not to an extent that would skew our results 
significantly.  
 
Figure 21 Forward-sideward-scatter analysis of PBMC incubated for 30 
minutes with varying concentrations of SNA. Note the extended dead-cell-
fraction in the left panel that extends to the left and seems to be associated 
with the SNA-concentration. Comparison of the percentages of dead cells of 
the whole diagram, however, provides no evidence that a concentration of 6.66 
μg/mL has a significantly greater cytotoxic effect than smaller concentrations. 
α1,2-linked fucose residues detected with the help of UEA-I 
UEA-I (Ulex europaeus agglutinin I; also known as gorse or furze) is a lectin 
that binds specifically to α1,2-linked fucose residues (Sughii, Kabat et al. 
1982).  
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Fascinatingly, in our study the α1,2 fucosylation of immune cells was similar to 
their α2,3 sialylation (Figure 5 on p. 37 and Figure 7 on p. 41): The expression 
of both types of sugar residues (α1,2-linked fucose and α2,3-linked sialic acids) 
was decreased on B cells from RRMS patients receiving natalizumab 
treatment. However, the α1,2 fucosylation of CD4 T cells was not subject to 
any changes. What stands out in the assessment of these data is that Th2 
cells were highly reactive with UEA-I which points to plenty of α1,2-linked 
fucose residues on their surface. This parallels the binding behaviour of MAL to 
Th2 cells (see Figure 12, page 46).  
Because CD22 is an antigen expressed mainly by B cells (see below, Nitschke 
2009) we expected the frequency of UEA+CD22+ cells to be similar to 
UEA+CD20+ cells. Similarly to the findings in CD20+ cells, UEA binding to 
CD22+ cells seems to decrease under natalizumab (Figure 7, page 41).  
CD22 
CD22 belongs to the family of siglecs which are members of the 
immunoglobulin super family that bind to sialic acids (a quality that they share 
with lectins). CD22 is a cell surface receptor that occurs in the membrane of B 
cells (Nitschke 2009) and to a lesser extent in the membrane of dendritic cells 
(Reineks, Osei et al. 2009). An important feature of CD22 is its highly specific 
binding site for α2,6-sialic acids whose ligation can inhibit intracellular 
signalling by suppressing Ca++ influx. Mouse models showed that CD22 is a 
negative regulator of B cell activation (Varki and Crocker 2009). It is thus 
believed that whenever an antigen-presenting cell that co-expresses α2,6 sialic 
acids encounters a B cell the immune response of that B cell will be reduced; it 
has been suggested that CD22 might therefore prevent B cells from 
overstimulation, or that, conversely, an impaired function of the CD22 molecule 
on B cells might favour autoimmunity (reviewed by Poe and Tedder 2012).  
Considering the possibly immunosuppressive effects of CD22 expression, we 
sought to examine whether B cells obtained from RRMS patients express 
fewer CD22 molecules than healthy controls. We found that B cells from 
natalizumab-treated patients show a somewhat weaker CD22-expression 
compared to healthy controls (p=0.004, Figure 8 and Table 5, page 43). 
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However, we were unable to detect a significant difference in CD22-expression 
between untreated RRMS patients and healthy controls. It should be noted, 
however, that an impaired function of the CD22 molecule may go unnoticed as 
long as only the presence and not the function of this molecule is analysed. 
Further tests that examine the signalling cascade in B cells from MS patients 
might shed more light on the role of the CD22 molecule in MS.  
Since CD22 has been primarily seen as a marker for B cells (as reviewed by 
Nitschke 2009) only few authors, including Reineks, Osei et al, 2009, have 
reported that dendritic cells (CD11c+ cells) express CD22. Our data confirm 
those findings in that in our study not only B cells but also dendritic cells 
(CD11c+ cells) showed reactivity with anti-CD22 (Figure 8 and Table 5, page 
43).  
Effect of immunomodulatory therapies 
Effects of natalizumab on the leukocyte composition 
T cells 
As we pointed out on page 50, we believe that CD4high cells are unactivated T 
cells and CD4low cells are activated T cells. Since we analysed CD4high and 
CD4low cells separately we had the chance to compare the numbers of 
activated CD4low cells, CD4high cells and CD4+ cells in general. The exact 
changes in the composition of peripheral blood cells under natalizumab 
treatment are still the subject of some debate, which is reflected by 
contradictory findings. While Skarica, Eckstein and colleagues (2011) could not 
detect an increase in CD4+ cells under natalizumab treatment other 
researchers report an increase in the numbers of lymphocytes, monocytes, 
eosinophils, and basophils in patients treated with natalizumab (Polman, 
O'Connor et al. 2006; Putzki, Baranwal et al. 2010). It has been suggested that 
this could be down to an increased release of all hematopoietic progenitor cells 
(Planas, Jelcic et al. 2011).  
Our results only partly support the expectation of a larger percentage of 
lymphocytes related to natalizumab treatment. In particular, in our study the 
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percentage of CD4high T cells was larger under natalizumab, whereas the 
portion of CD4low cells was smaller (see Figure 2 on page 31). In fact, the 
frequencies of CD4high and CD4low cells taken together even cancelled each 
other out so that the portion of CD4+ cells did not vary significantly from group 
to group (Figure 3, page 32). Contrary to expectation, our results suggest that 
natalizumab does not influence the percentage of CD4 T cells on the whole. 
Nonetheless, our numbers of CD4high cells are in keeping with what can be 
found about CD4 T cells in literature.  
One of the putative effects of natalizumab is to hinder CD4 T cells from leaving 
the blood vessels and entering the brain parenchyma (Baron, Madri et al. 
1993). If this effect were reflected in the relative numbers of peripheral T cells 
and T cell subsets, we would expect greater numbers of CD4 T cells in 
natalizumab-treated patients than in treatment-naive RRMS patients. While the 
distribution of CD4+ cells failed to back this assumption, CD4high cells 
occurred in greater frequencies in natalizumab-treated patients than in 
untreated RRMS-patients (Figure 2, page 31).  
In our opinion, CD4high cells are unactivated CD4 T cells (see page 50). It is 
the activated cells, however, that leave blood vessels to engage in 
inflammation. Hence, it is unclear, whether the effect of natalizumab, that stops 
cells from extravasating and traps them in the blood vessels, can account for 
our finding of a larger portion of CD4high cells in the blood of MS patients.  
B cells 
In our study the percentage of B cells in natalizumab-treated patients more 
than doubled (Table 1, Figure 2, page 31) which parallels reports of 
natalizumab-associated lymphocytosis (Polman, O'Connor et al. 2006; 
Krumbholz, Meinl et al. 2008; Skarica, Eckstein et al. 2011). Interestingly, a 
rise in the number of B cells under natalizumab led Planas, Jelcic and their 
colleagues to the hypothesis that an increased B cell mobilisation provides the 
JC virus with ideal breeding grounds (Planas, Jelcic et al. 2011).  
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Monocytes 
Although observations to the contrary have also been made (Polman, 
O'Connor et al. 2006), our data show an insignificant trend toward a decreased 
portion of monocytes under natalizumab (Figure 2). Similarly, a drop in relative 
numbers of monocytes under natalizumab has also been reported (Skarica, 
Eckstein et al. 2011).  
Cytotoxic T cells 
The effect of natalizumab on cytotoxic T cells (CD8+ cells) has still not been 
fully understood. Some researchers were unable to detect an increase in the 
number of cytotoxic T cells under natalizumab (Skarica, Eckstein et al. 2011), 
while other research groups found that CD8+ cells increased 1.7-fold under 
natalizumab therapy (Putzki, Baranwal et al. 2010). The latter figure is close to 
what we could find, namely a 1.5 fold increase in the percentage of CD8+ cells 
under natalizumab (Table 1, Figure 2, page 31). 
Effects of interferon-β on the composition of leukocytes  
Van Boxel-Dezaire, Zula and their colleagues (2010) report a number of effects 
on the composition of leukocytes in response to interferon-β, most of which we 
were unable to reproduce in our study.  
For example, van Boxel-Dezaire and Zula found an IFN-β-related increase in 
the survival of T cells and B cells (van Boxel-Dezaire, Zula et al. 2010), which 
we could not find. In our study, neither the percentage of B cells in IFN-β-
treated patients (Figure 2), nor the percentage of T cells (all CD4+ cells, Figure 
3) differed considerably from the ones in control groups.  
Furthermore, van Boxel-Dezaire, Zula and colleagues (2010) report a higher 
apoptosis rate in monocytes when exposed to IFN-β. We can only partly 
support this finding as our study shows an insignificant trend towards a smaller 
portion of monocytes under IFN-β-treatment (p=0.225 compared to untreated 
MS patients, Figure 2, page 31).  
A possible explanation for why our results did not completely match van Boxel-
Dezaire and Zula’s findings is that they ran an in vitro experiment in which they 
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exposed freshly drawn blood to IFN-β in culture-dishes. Unfortunately, they did 
not state the exact concentration of IFN-β at which they stimulated the blood 
cells. However, in different experiments carried out by the same group other 
kinds of interferon were added to the cells at concentrations between 3 × 103 
IU/μl and 10 × 103 IU/μl (van Boxel-Dezaire, Zula et al. 2010). It is difficult to 
say how this corresponds to the serum levels of INF-β in the patients that 
participated in our study. The half life (T1/2) of IFN-β is approximately 8 hours 
(Lahoz, Kauffman et al. 2009) and thus serum levels in patients who get an 
IFN-β-injection every other day may be not as steady as in an in vitro 
experiment.  
Subsets of T cells (Th1 and Th17, Th2 and Treg) play a role in the 
pathogenesis of MS or its prevention, respectively. Therefore, it is interesting to 
examine whether IFN-β has an effect on T helper cell subsets.  
For example, Skrzipek, Vogelgesang and colleagues (2011) activated CD4+ 
cells obtained from treatment-naive RRMS patients with anti-CD3/CD28 in the 
presence of IFN-β1b. They report a reduced IFN-γ secretion by CD4+ under 
the influence of IFN-β1b (Skrzipek, Vogelgesang et al. 2011). Their finding is 
interesting in light of an earlier report suggesting that IFN-β favours the 
differentiation of naive CD4 T cells into Th2 cells rather than into Th1 cells 
(Martin-Saavedra, Gonzalez-Garcia et al. 2008; Skrzipek, Vogelgesang et al. 
2011).  
One way to further analyse the influence of IFN-β on the differentiation and 
surface glycosylation of T helper subsets would be to purify naive CD4 T cells 
and differentiate them into T helper subsets over at least 10 days. This method 
would involve a repeated activation of these naive CD4 T cells with anti-
CD3/CD28 in the presence or absence of IFN-β and appropriate cytokines. 
The percentage of the respective T helper subset population and their surface 
glycosylation could then be determined using flow cytometry (personal 
correspondence with PD Dr. Ghoreschi and PD Dr. Bischof, both UKT 
Tübingen).  
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Conclusions 
In this study we showed that IFN-β treatment was associated with changes in 
glycan patterns not only on CD4 T cells but also on B cells. Specifically, IFN-β 
treatment was associated with lower α2,3-sialylation on CD4high cells and a 
trend toward this direction on B cells. Furthermore, α1,2-fucosylation on B cells 
was also markedly reduced under the influence of IFN-β treatment. As regards 
the frequency of whole cell populations, IFN-β treatment was associated with 
an increase in the portion of cytotoxic T cells.  
Interestingly, some of the changes noted in the presence of IFN-β treatment 
were also seen in trial subjects treated with natalizumab: Both α2,3-sialylation 
and α1,2-fucosylation were reduced on B cells, suggesting an impact of 
natalizumab treatment on the sialylation of B cells.  
In addition, we documented changes in the relative frequencies of various 
different types of immune cells that might well be related to the influence of 
natalizumab treatment:  
The portion of CD4high cells was larger while the portion of CD4low cells was 
smaller under natalizumab treatment. Furthermore, the percentages of 
cytotoxic T cells and B cells were increased. We confirm previous reports that 
document CD22 expression on B cells and dendritic cells. Furthermore, we 
found a lower CD22 expression on B cells in natalizumab-treated RRMS 
patients. The assessment of the sialylation of T cell subsets showed plenty of 
binding sites for UEA-I and MAL-II on Th2 cells, pointing to an increased α1,2-
fucosylation and α2,3-sialylation compared to the other T cell subsets. SNA 
bound abundantly to all cell types under study.  
We conclude that both natalizumab and IFN-β seem to influence the 
composition of the white blood cell count and the sialylation/fucosylation of 
various immune cells. To further clarify the impact of certain types of sialylation 
on immune cells, functional tests and experiments based on the data that we 
generated are necessary. In particular, proliferation assays with α1,2-
fucosylated and α2,3-sialylated Th2 cells or the influence of IFN-β on the 
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cytokine production of T helper subsets might reveal further insight into the 
field.  
Summary  
It is believed that the inflammation of the CNS in MS is driven by Th1 and Th17 
cells and that it is then maintained by other cell types of the immune system 
such as B cells or plasma cells. Different cell types, such as regulatory T cells, 
are thought to fight off inflammation and thus have a beneficial effect on the 
course of the disease. There is also the hypothesis that ligation of certain 
surface molecules, such as CD22, influences the reactivity of immune cells 
through intracellular signalling. To determine the frequency and the glycan 
pattern of the respective cell types, immune cells obtained from natalizumab- 
and IFN-β-treated RRMS patients and controls were stained with cell type 
specific antibodies and glycan specific lectins (MAL-II, UEA-I, SNA and anti-
CD22) and analysed flow cytometrically. Our findings parallel previous reports 
insofar as we saw an increase in the portion of B cells and cytotoxic T cells in 
natalizumab-treated patients. A hitherto undescribed phenomenon that 
occurred in natalizumab-treated patients was a reduced expression of CD22, 
α1,2-fucosylation and α2,3-sialylation on B cells. IFN-β treatment was 
associated with an increase in the percentage of cytotoxic T cells as well as 
with a reduced α2,3-sialylation of CD4high cells. In addition, we found that Th2 
cells obtained from healthy donors expressed markedly larger amounts of 
α1,2-fucosylation and α2,3-sialylation than any other T cell subset. The portion 
of regulatory T cells was neither altered by MS itself nor by its 
immunomodulatory treatment.  
 Zusammenfassung 
Es wird angenommen, dass die Entzündung des ZNS bei MS von Th1 und 
Th17 Zellen angetrieben wird und durch andere Arten von Immunzellen, wie B-
Zellen oder Plasmazellen aufrechterhalten wird. Außerdem wird vermutet, dass 
regulatorische T-Zellen die Entzündungsreaktion unterdrücken und somit eine 
positive Wirkung auf den Verlauf der Erkrankung haben. Es besteht außerdem 
die Hypothese, dass die Ligation bestimmter Oberflächenmoleküle, wie CD22, 
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die Reaktivität von Immunzellen durch intrazelluläre Signalisierung 
beeinflussen. Um die Häufigkeit und das Glycanmuster der jeweiligen 
Zelltypen zu bestimmen, wurden Immunzellen mit zelltyp-spezifischen 
Antikörpern und glycan-spezifischen Lektinen (MAL-II, UEA-I, SNA-und Anti-
CD22) gefärbt und durchflusszytometrisch untersucht. Die Zellen wurden von 
RRMS-Patienten, die mit Natalizumab und IFN-β behandelt wurden, und von 
Kontrollgruppen gewonnen. Ein Teil unsere Ergebnisse (die Zunahme der 
relativen Anzahl von B-Zellen und zytotoxischen T-Zellen in Natalizumab-
behandelten Patienten) entspricht früheren Befunden. Ein bisher 
unbeschriebenes Phänomen, das wir in der Gruppe der mit Natalizumab 
behandelten Patienten fanden, ist eine verminderte Expression von CD22, 
α1,2-Fucosylierung und α2,3-Sialylierung auf B-Zellen. Die Behandlung mit 
IFN-β war sowohl mit einem erhöhten Anteil z ytotoxischer T-Zellen als auch 
mit einer reduzierten α2,3-Sialylierung von CD4high Zellen assoziiert. 
Zusätzlich fanden wir, dass die α1,2 -Fucosylierung und α2,3-Sialylierung auf 
der Oberfläche von Th2-Zellen von gesunden Spendern deutlich höher im 
Vergleich zu anderen T-Zell-Untergruppen war. Der Anteil von regulatorischen 
T-Zellen wurde weder durch MS selbst noch durch ihre immunmodulatorische 
Behandlung verändert.  
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